West Pharmaceutical Services (WST) Cash from Operations (2009 - 2026)

West Pharmaceutical Services (WST) has reported Cash from Operations for 18 consecutive years, with 124000000.0 the latest figure, recorded in Q2 2026.

• Quarterly Cash from Operations fell 29.98% year-over-year to 124000000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 662200000.0 (down 2.14% YoY) and the FY2025 annual result came in at 754800000.0, up 15.52% from the prior year.
• Cash from Operations improved to 124000000.0 in Q2 2026 per WST's latest filing, from 89900000.0 in the prior quarter.
• Over the last five years, Cash from Operations for WST reached as high as 251100000.0 in Q4 2025 and fell as low as 89900000.0 in Q1 2026.
• A 5-year average of 173477777.78 and a median of 171150000.0 in 2022 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2022 — Cash from Operations jumped 70.46% — and 2026, when it tumbled 30.53%.
• Year by year, Cash from Operations stood at 230800000.0 in 2022, then rose by 3.6% to 239100000.0 in 2023, then dropped by 20.49% to 190100000.0 in 2024, then surged by 32.09% to 251100000.0 in 2025, then plunged by 50.62% to 124000000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 124000000.0, 89900000.0, and 251100000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.